No Detail Found!

Association of fibrinogen and plasminogen activator inhibitor-1 with diabetes mellitus

Author(s)
Iffat Ara Aziz Department of Biochemistry, Baqai Medical University,Karachi,Pakistan
Asher Fawwad Department of Biochemistry, Baqai Medical University,Karachi,Pakistan
Iftikhar Ahmed Siddiqui Department of Biochemistry, Baqai Medical University,Karachi,Pakistan
Kahkashan Perveen Department of Biochemistry, Baqai Medical University,Karachi,Pakistan
Ruqaya Nangrejo Department of Physiology, Baqai Medical University,Karachi,Pakistan
Nazish Waris Baqai Institute of Diabetology and Endocrinology, Baqai Medical University,Karachi,Pakistan
Abdul Basit Baqai Institute of Diabetology and Endocrinology, Baqai Medical University,Karachi,Pakistan
Abstract
As the state of hyperfibrinogenemia in diabetes patients occurs due to hyperglycemia which also activates the coagulative cascade ultimately stimulating hepatic fibrinogen synthesis and thus increases clotting factors and PAI-1 levels in the blood. Therefore, in present study our aim is to correlate between type of diabetes and plasma fibrinogen level and plasminogen activator inhibitor-1. This cross sectional study was conducted at Baqai Medical University (BMU) with the collaboration of Baqai Institute of Diabetology and Endocrinology, Karachi. Data was collected from 161 subjects, out of which 51 were control and 55 were subjects in each type 1 diabetes, type 2 diabetes simultaneously. Anthropometric measurements included measurement of weight, height, BMI and blood pressure which were done for each participant. Blood sugar levels and glycated hemoglobin, lipid profile, PAI-1 and fibrinogen were measured in cases and controls. Out of 161 subjects, 80 (49.7%) were male and 81 (50.3%) were female with mean age of 37.75±1.25 years. Fibrinogen level was significantly decreased in healthy subjects as compared to type 1 and type 2 diabetes subjects P-value<0.0001, however no significant difference was observed in fibrinogen level of type 1 diabetes subjects and type 2 diabetes subjects. Plasminogen activator inhibitor-1 of type 2 diabetes subjects was significantly increased as compared to type 1 diabetes subjects (P-value<0.05) but not significantly different to healthy subjects (P-value>0.05). Since, fibrinogen and plasminogen activator inhibitor type 1 was increased in diabetes patients this predisposed them to increased risk of coronary artery disease, our study further supports the clinical observation that diabetes is a thrombophillic condition.
Publication Details
Page(s) 165-169
Published Journal: Pakistan Journal of Pharmaceutical Sciences, Volume: 35, Issue: Sup-1, Year: 2022

Request the full text from PASTIC

Keywords
Fibrinogen, plasminogen activator inhibitor-1, Diabetes mellitus, Diabetes mellitus, Diabetes Mellitus
References
Agarwal C,Bansal K,Pujani M,Singh K,Chauhan V,Rana D,Lukhmana S D .2019 .Association of coagulation profile with microvascular complications and glycemic control in type 2 diabetes mellitus - A study at a tertiary care center in Delhi. Hematol Transfus Cell Ther. , 41(1) : 31-36.
Abouammoh NA,Alshamrani MA .2020 .Knowledge about diabetes and glycemic control among diabetic patients in Saudi Arabia. J. Diabetes Res., : 1-6.
Antunes BM,Rossi FE,Oyama LM,Rosa-Neto JC,Lira FS .2020 .Exercise intensity and physical fitness modulate lipoproteins profile during acute aerobic exercise session. Sci. Rep, 10(1) : 1-8.
Chen R,Yan J,Liu P,Wang Z,Wang C .2017 .Plasminogen activator inhibitor links obesity and thrombotic cerebrovascular diseases: The roles of PAI1 and obesity on stroke. Metab. Brain Dis, 32(3) : 667-673.
Dastgheib SA,Najafi F,Shajari A,Bahrami R,Asadian F,Sadeghizadeh-Yazdi J,Akbarian E,Emarati SA,Neamatzadeh H SA .2020 .Association of plasminogen activator inhibitor-1 4G5G Polymorphism with risk of diabetic nephropathy and retinopathy: A systematic review and meta-analysis. JDMD, : 1-12.
El Wakeel MA,Abou-El-Asrar Mohamed,El-Kassas GM,Elabd MA,Zeid DA,Sabry RN,Awadallah EMAN .2017 .Urinary markers of oxidative DNA damage in Type 1 diabetic children: Relation to microvascular complications. Asian J. Pharm. Clin. Res., 10(10) : 318-22.
El Sayed ZH,Ismail SM,ELhakeem HA SM .2018 .Evaluation of plasma fibrinogen and plasminogen activator inhibitor-1 in type 2 diabetes mellitus patients with coronary artery disease. SSAMFG, 2(3) : 252.
Wolfrum Grandl G,C Grandl G .2018 .February. Hemostasis, endothelial stress, inflammation, and the metabolic syndrome. Semin Immunopathol, 40(2) : 215-224.
Jung RG,Simard T,Labinaz A,Ramirez FD,Di Santo P,Motazedian P,Rochman R,Gaudet C,Faraz MA,Beanlands RS,Hibbert B .2018 .Role of plasminogen activator inhibitor-1 in coronary pathophysiology. Thromb. Res,, 164 : 54-62.
Lee SJ,Hong JM,Lee SE,Kang DR,Ovbiagele B,Demchuk AM,Lee JS .2017 .Association of fibrinogen level with early neurological deterioration among acute ischemic stroke patients with diabetes. BMC Neurology, 17(1) : 1-7.
Liu S,Li Y,Fan X,Li K,Xu C,Zhang L,Luo M,Wang L,Li R,Wu J .2020 .Transplantation of adipose tissue lacking PAI-1 improves glucose tolerance and attenuates cardiac metabolic abnormalities in high-fat diet-induced obesity. Adipocyte, 9(1) : 170-178.
Persil-Ozkan O,Yigit E,Yigit Z E .2019 .Does weight loss affect the parameters that are metabolically related to cardiovascular diseases? Saudi Med. , 40(4) : 347.
Razak MKA,Sultan AA .2019 .The importance of measurement of plasma fibrinogen level among patients with type-2 diabetes mellitus. Diabetes Metab Syndr Clinical Research & Reviews, 13(2) : 1151-1158.
Recinella L,Orlando G,Ferrante C,Chiavaroli A,Brunetti L,Leone S L .2020 .Adipokines: New potential therapeutic target for obesity and metabolic, rheumatic, and cardiovascular diseases. Front. Physiol., 11 : 1-32.
Song C,Burgess S,Eicher JD,'Donnell O,Johnson CJ,AD CJ,Sabater-Lleal Huang J,M Huang J .2017 .Causal effect of plasminogen activator inhibitor type 1 on coronary heart disease. J. Am. Heart Assoc., 6(6) : e004918.
Mohiuddin SS .2018 .Correlation of glycemic status with plasma fibrinogen level in insulin dependent as well as noninsulin dependent diabetic patients. J. Endocrinol. Diab., 5(5) : 1-6.
Somodi S,Seres I,Lorincz H,Harangi M,Fulop P,Paragh G .2018 .Plasminogen activator inhibitor-1 level correlates with lipoprotein subfractions in obese nondiabetic subjects. Int. J. Endocrinol., (-3) : 1-9.
Sobolewski K,Radparvar S,Wong C,Johnston J .2018 .Blood, blood components, plasma, and plasma products. Side Eff. Drugs Annu, 40 : 415-429.
Shemran KA .2051 .Study the elevation of fibrinogen level in plasma patients with diabetes mellitus type 2 in babylon governorate. Indian J. Forensic Med, 14(4) : .
Tabakcı MM,Gerin F,Sunbul M,Toprak C,Durmus HI,Demir S,Arslantas U,Cersit S,Batgerel U,Kargın R U .2017 .Relation of plasma fibrinogen level with the presence, severity, and complexity of coronary artery disease. Clin. Appl, 23(6) : 638-644.
Vousden KA,Lundqvist T,Popovic B,Naiman B,Carruthers AM,Newton P,Johnson DJ,Pomowski A,Wilkinson T,Dufner P,de Mendez I P .2019 .Discovery and characterisation of an antibody that selectively modulates the inhibitory activity of plasminogen activator inhibitor-1. , 9(1) : 1-12.
Zhang J,Wang Y,Zhang R,Li H,Han Q,Wu Y,Wang S,Guo R,Wang T,Li L,Liu F L .2018 .Serum fibrinogen predicts diabetic ESRD in patients with type 2 diabetes mellitus. Diabetes Res. Clin. Pract, 141 : 1-9.
0

Citations

0

Downloads

10

Views